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markers of BRCA1-dysfunction will be essential to translate an
understanding of defective DNA repair into targeted treatments
for this poor prognosis subtype.
Materials and methods: Twenty-two patients with triple-
negative breast cancer (TNBC) were treated with neoadjuvant
platinum-based chemotherapy followed by surgery. Pathologic
treatment response was assessed in correlation with biomarkers
of BRCA1-dysfunction. Pathological response was evaluated
according to the Chevallier classification (Ch). All patients were
screened for germ-line mutations in BRCA1 (185delAG, 5382insC,
4153delA, 4158A/G, C61G) and BRCA2 (6174delT). All samples
negative for germ-line mutations in BRCA1 and BRCA2 then
submitted to BRCA1-dysfunction screening. Biomarkers of
BRCA1-dysfunction included: BRCA1 somatic mutations (C61G,
185delAG, 5382insC), promoter methylation of BRCA1, low BRCA1
mRNA expression, high ID4 mRNA expression, low RAD51 mRNA
expression, PTEN (T4721C) mutation, p53 (Arg72Pro, Pro72Pro)
mutations. Quantitative reverse transcriptase polymerase chain
reaction (qRT-PCR), polymerase chain reaction-single-strand
conformation polymorphism (PCR-SSCP), methylation-specific
PCR were used for BRCA1-dysfunction analysis.
Results: Twelve patients (54.5%) achieved a pathological com-
plete response (pCR) (Ch1+ Ch2). Ten patients (45.5%) had a resid-
ual disease (Ch3+ Ch4). BRCA1 mRNA expression was absent in
16/22 (72.7%) patients, low in 5/22 (22.7%). 11/21 (52.4%) patients
with other than normal BRCA1 mRNA expression achieved a
pCR. BRCA1 promoter methylation was detected in 9/22 (40.9%).
6/9 patients with BRCA1 promoter methylation achieved a pCR.
RAD51 mRNA levels were low in 14/22 (63.6%), high in 1/22
(4.5%). 8/14 (57.1%) patients with other than normal RAD51 mRNA
expression achieved a pCR.
High ID4mRNA levelswere determined in 5/22 (22.7%). 3/5 (60%)
patients with high ID4 mRNA expression achieved a pCR. p53
(Arg72Pro, Pro72Pro) mutations were identified in 12/22 (54.5%).
Nopatient had PTEN (T4721C)mutation. No statistically significant
correlation was found between the BRCA1 mRNA expression,
BRCA1 promoter methylation, RAD51 mRNA expression, high ID4
mRNA levels, p53 (Arg72Pro, Pro72Pro) mutations and pCR to
neoadjuvant platinum-based chemotherapy (p > 0.05). Eleven
patients had BRCA1 somatic mutations: 6/22 (27.3%) – BRCA1
5382insC, 4/22 (18.2%) – BRCA1 185delAG, 3/22 (13.6%) – BRCA1
C61G. 3/4 patients with BRCA1 185delAG mutation had BRCA1
C61G mutation. BRCA1 LOH was detected in 1/22 (4.5%) patient.
All patients with BRCA1 5382insC mutation achieved a pCR
(p = 0.01). All patients with BRCA1 185delAG mutation and BRCA1
C61G mutation had residual disease (0.04 and 0.1, accordingly).
Conclusion: BRCA1 5382insC somatic mutation is associated
with good response to neoadjuvant platinum based chemother-
apy (p = 0.01). BRCA1 185delAG and BRCA1 C61G mutations in
the BRCA1 RING domain may predict resistance to neoadjuvant
platinum-based chemotherapy (0.04 and 0.1, accordingly).
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Background: Tumor-associated macrophages play a main role
in tumor progression and dissemination. Taking into account
the high heterogeneicity of tumor the different clinical impact
of macrophages, infiltrating different sites of tumor, could be
expected. The aim was to detect the level of CD68+ cells (macro-
phages) in the different site of stroma in breast tumor in compar-
ison to clinical course.
Materials and methods: One thirty-six women with nonspeci-
fic invasive breast cancer T1-4N0-3M0, who were treated in Gen-
eral Oncology Department of Tomsk Cancer Research Institute
(Tomsk, Russia), were included in the present study. Patients did
not receive preoperative treatment. The material was fixed in
10–12% neutral formalin. Preparation of the histological material
was carried out according to standard procedures. Morphological
examination of the surgical specimens was performed by the
standard method using a light microscope ‘‘Carl Zeiss Axio Lab.
A1” (Germany) and slidescanner ‘‘MiraxMidiZeiss” (Germany).
Metastatic lesion was detected in regional lymph nodes.
Immunohistochemical study was performed according to stan-
dard procedures. Cytoplasmic expression of these markers was
determined in the inflammatory cell infiltrate of different tumor
segments: (1) in areas with soft fibrous stroma; (2) in areas with
coarse fibrous stroma; (3) in the areas of the so-called ‘‘maximum
stromal-and-parenchymal relationship” where the individual
tumor cells, short strands and groups of tumor cells arranged in
soft fibrous stroma; (4) among parenchymal elements; (5) in gaps
of ductal tumor structures. Double-stained immunofluorescence
was performed according to standard procedures using Leica
TCS SP2 laser-scanning spectral confocal microscope (Germany).
The following primary antibodies were used: mouse monoclonal
anti-human CD68 (BD Biosciences) and rabbit polyclonal anti-
stabilin-1 or RS1 (marker of M2 macrophages).
Results: The highest expression of CD68 in the inflammatory
cell infiltrate was detected more frequently in areas with soft
fibrous stroma (54%) or the so-called ‘‘maximum stromal-and-
parenchymal relationship” (79%) in patients with breast cancer.
The lowest expression of CD68 was observed in areas with coarse
fiber stroma (23%). The CD68-positive cells of the inflammatory
infiltrate were located between parenchymal elements of tumor
(88%). Inverse correlation (R = 0.67; p = 0.02) observed between
tumor size and the expression of CD68 in the cells of the inflam-
matory infiltrate in gaps of tubular tumor structures. The CD68
expression in cells of the inflammatory tumor infiltrate was cor-
related with the presence of metastatic regional lymph nodes. It
was found that in the case of the lymph node metastases the
average score of CD68 expression in cells of ductal gaps tumor
structures was lower (1.4 ± 0.5) in comparison with the negative
lymph nodes case (3.1 ± 1.0; F = 10.9; p = 0.007). Same time no cor-
relation between the CD68 expression in the inflammatory cell
tumor infiltrate and the rate of tumor malignancy was found.
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Using confocal microscopy domination of CD68+/RS1+ cells were
found.
Conclusion: So, low CD68 expression level in ductal gaps tumor
structures is associated with the presence of metastatic regional
lymph nodes.
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Background: To evaluate the expression of markers of sensitiv-
ity to chemotherapy in patients various solid tumors.
Materials and methods: The work includes paraffin blocks
NSCLC patients (n = 486); CRC (n = 262); Breast cancer (n = 55); cer-
vical cancer (n = 19); kidney (n = 35); squamous head and neck
cancer (n = 15); stomach (n = 51); ovarian (n = 25); melanoma
(n = 58); soft tissue sarcomas (n = 52). On our panel discussed
the spectrum of expression of enzymes DPD, TP, TS, ERCC1,
b-tubulin. Measurement of the expression of these genes pro-
duced by polymerase chain reaction in real time according to
the method developed at the Institute of Oncology. NN Petrova.
Results: The combination of markers of sensitivity to fluoropy-
rimidine (low levels of DPD, TS, and low/high TP) was observed in
patients with NSCLC in 30.9%, 41.9% in colorectal cancer, breast
cancer in 31.1%, renal cell carcinona 41.1%, head and neck carci-
noma in 14.3%, of gastric cancer in 42.5% melanoma in 39.5% of
cases. Marker sensitivity to platinum drugs (low ERCC1) occurs
in patients with NSCLC in 68.8%, 57.1% in colorectal cancer, breast
cancer in 55.0%, renal cancer in 70.8% of squamous cell carci-
noma of the head and neck 50, 0% of gastric cancer in 87.9% in
melanoma 63.6% of cases. Marker, is an indirect measure of sen-
sitivity to taxane drugs (low b-tubulin) in patients with NSCLC
diagnosed in 72.7% of cases, in 75% of colorectal cancer, breast
cancer in 66.7%, renal cancer in 92.3% of gastric cancer to
86.6%, melanoma in 73.5%.
Conclusion: The expression of markers in tumor tissue is
heterogeneous. Significant heterogeneity of expression of predic-
tive marker indicates on one hand the futility of the empirical
approach to the choice of therapy, and on the other the need
for their determination in all patients. Information about the
molecular and genetic features of the tumor can afford to
individualize the choice of drug. Objective data about the
informativeness of molecular genetic markers can be obtained
on the basis of randomized clinical trials.
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Background: In previous experiments the self-dependent
antitumor effect of magnetite nanoparticles (NPs) injected in
peritumoral area in form of magnetic fluid (MF) was shown.
Elucidation of the mechanisms of this phenomenon is of theoret-
ical and practical interest. The aim of the study was to investigate
the cellular and ultrastructural changes in the tissue tumors
regressed under the influence of magnetite NPs, as well as the
composition of the cells of the immune system in the peritumoral
area.
Materials and methods: The study was carried on white male
rats, 180–200 g, with transplanted sarcoma 45 (59) or Pliss
lymphosarcoma (50). Special antitumor agents were not used.
Magnetite NPs (10 ± 2 nm) were applied in the form of the
water-based MF. Original MF (20 kA/m) was diluted with saline
in different degree and was injected into peritumoral zone along
the tumor borders at a distance of 1.5 cm twice a week in a vol-
ume of 0.4–0.9 ml (depending on the animal weight) within
3 weeks. Special anti-tumor agents were not used. At the end of
the experiments fragments of the tumor and surrounding tissue
were taken for research. The study of changes in the tumor and
peritumoral area were performed by the methods of cytology, his-
tology, histochemistry, electron microscopy (microscope JEOL
JEM-1011, Japan), flow cytometry, X-ray fluorescence spectroscopy
(spectrometer M4 Tornado Bruker).
Results: At a dilution of the original MF in 30 times the treat-
ment was effective in 75% of animals. Complete and partial (more
than 2-fold) tumor regression was observed in 2/3 cases. In rats
with Pliss lymphosarcoma tumor regression on 70–100% has been
reported in 20–40% cases. The results of microscopic examination
of sarcoma 45 with partial regression showed significant changes
in their immune microenvironment compared with the cases of
progressive tumor growth (p < 0.05–0.01). This was expressed in
the increase in the number of lymphocytes and plasmacytes
(respectively, in 12 and 2.5 fold), and in the appearance of
macrophages and basophils that were missing in tumors with
progressive growth. The results of flow cytometry of tissue from
the tumor as well as from peritumoral zone indicate the predom-
inance of plasmacytes in the case of inhibition of tumor growth
and increasing the proportion of mature T lymphocytes in the
cases of tumor regression (more than 1.5 times, p < 0.05). By
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